Your browser doesn't support javascript.
loading
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma.
Qin, Shukui; Chan, Stephen Lam; Sukeepaisarnjaroen, Wattana; Han, Guohong; Choo, Su Pin; Sriuranpong, Virote; Pan, Hongming; Yau, Thomas; Guo, Yabing; Chen, Minshan; Ren, Zhenggang; Xu, Jianming; Yen, Chia-Jui; Lin, Zhong-Zhe; Manenti, Luigi; Gu, Yi; Sun, Yongjian; Tiedt, Ralph; Hao, Lu; Song, Wenjie; Tanwandee, Tawesak.
Afiliação
  • Qin S; PLA Cancer Center, Nanjing Bayi Hospital, Nanjing 210002, China.
  • Chan SL; Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.
  • Sukeepaisarnjaroen W; Department of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand.
  • Han G; Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
  • Choo SP; Division of Medical Oncology, National Cancer Center Singapore, Singapore.
  • Sriuranpong V; Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Pan H; Department of Medical Oncology, Sir Run Shaw Hospital, Zhejiang University, Hangzhou, China.
  • Yau T; Department of Surgery, Queen Mary Hospital, University of Hong Kong, Hong Kong, China.
  • Guo Y; Nanfang Hospital, Guangzhou Southern Medical University, Guangzhou, China.
  • Chen M; Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Ren Z; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Xu J; Department of Gastrointestinal Oncology, 307 Hospital of People's Liberation Army, Beijing, China.
  • Yen CJ; Department of Internal Medicine, National Cheng Kung University Hospital, Tainan City.
  • Lin ZZ; Department of Oncology, National Taiwan University Hospital, Taipei City.
  • Manenti L; Translational Clinical Oncology, Novartis Institutes for BioMedical Research, East Hanover, NJ, USA.
  • Gu Y; PK Sciences, China Novartis Institutes for BioMedical Research, Shanghai, China.
  • Sun Y; Translational Clinical Oncology, China Novartis Institutes for BioMedical Research, Shanghai, China.
  • Tiedt R; Novartis Institutes for BioMedical Research, Basel, Basel-Stadt, Switzerland.
  • Hao L; Translational Clinical Oncology, China Novartis Institutes for BioMedical Research, Shanghai, China.
  • Song W; Translational Clinical Oncology, China Novartis Institutes for BioMedical Research, Shanghai, China.
  • Tanwandee T; Division of Gastroenterology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Ther Adv Med Oncol ; 11: 1758835919889001, 2019.
Article em En | MEDLINE | ID: mdl-31853265

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article